The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms

Elotuzumab is a humanized therapeutic monoclonal antibody directed to the surface glycoprotein SLAMF7 (CS1, CRACC, CD319), which is highly expressed on multiple myeloma (MM) tumor cells. Improved clinical outcomes have been observed following treatment of MM patients with elotuzumab in combination w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Pazina, Tatiana, James, Ashley M., MacFarlane, Alexander W., Bezman, Natalie A., Henning, Karla A., Bee, Christine, Graziano, Robert F., Robbins, Michael D., Cohen, Adam D., Campbell, Kerry S.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5599094/
https://ncbi.nlm.nih.gov/pubmed/28932638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1339853
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados